Skip to main content
Top
Published in: Cancer Cell International 1/2015

Open Access 01-12-2015 | Primary research

Observations on the expression of human papillomavirus major capsid protein in HeLa cells

Authors: Chang-Yi Xiao, Bing-Bing Fu, Zhi-Ying Li, Gohar Mushtaq, Mohammad Amjad Kamal, Jia-Hua Li, Gui-Cheng Tang, Shuo-Shuang Xiao

Published in: Cancer Cell International | Issue 1/2015

Login to get access

Abstract

Background

The goal of this study was to identify the nature of the inclusion bodies that have been found in HeLa cells (cervical cancer immortal cell line) by electron microscope and to determine whether the major capsid protein (L1) of human papillomavirus (HPV) can be expressed in HPV-positive uterine cervix cancer cells.

Methods

HPV L1 protein expression in HeLa cells was detected with anti-HPV L1 multivalent mice monoclonal antibody and rabbit polyclonal anti-HPV L1 antibody by ELISA, light microscope immunohistochemistry, electron microscope immunocytochemistry and Western blotting assays. Reverse transcriptional PCR (RT-PCR) was performed to detect the transcription of L1 mRNA in HeLa cells. The immortalized human keratinocyte HeCat was used as the negative control.

Results

HPV L1 proteins reacted positively in the lysate of HeLa cells by ELISA assays. HRP labeled light microscope immunohistochemistry assay showed that there was a strong HPV L1 positive reaction in HeLa cells. Under the electron microscope, irregular shaped inclusion bodies, assembled by many small and uniform granules, had been observed in the cytoplasm of some HeLa cells. These granules could be labeled by the colloidal gold carried by HPV L1 antibody. The Western blotting assay showed that there was a L1 reaction strap at 80–85 kDa in the HeLa cell lysates, hence demonstrating the existence of HPV18 L1 in HeLa cells. RT-PCR assay showed that the L1 mRNA was transcribed in HeLa cells.

Conclusions

The inclusion bodies found in the cytoplasm of HeLa cells are composed of HPV18 L1 protein. Since HeLa cell line is a type of cervical cancer cells, this implies that HeLa cells have the ability to express HPV L1 proteins.
Literature
1.
go back to reference Giroglou T, Sapp M, Lane C, Fligge C, Christensen ND, Streeck RE, et al. Immunological analyses of human papillomavirus capsids. Vaccine. 2001;19:1783–93.PubMedCrossRef Giroglou T, Sapp M, Lane C, Fligge C, Christensen ND, Streeck RE, et al. Immunological analyses of human papillomavirus capsids. Vaccine. 2001;19:1783–93.PubMedCrossRef
2.
go back to reference Ohlschläger P, Osen W, Dell K, Faath S, Garcea RL, Jochmus I, et al. Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice. J Virol. 2003;77:4635–45.PubMedCentralPubMedCrossRef Ohlschläger P, Osen W, Dell K, Faath S, Garcea RL, Jochmus I, et al. Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice. J Virol. 2003;77:4635–45.PubMedCentralPubMedCrossRef
3.
go back to reference Thönes N, Müller M. Oral immunization with different assembly forms of the HPV 16 major capsid protein L1 induces neutralizing antibodies and cytotoxic T-lymphocytes. Virology. 2007;369:375–88.PubMedCrossRef Thönes N, Müller M. Oral immunization with different assembly forms of the HPV 16 major capsid protein L1 induces neutralizing antibodies and cytotoxic T-lymphocytes. Virology. 2007;369:375–88.PubMedCrossRef
4.
go back to reference Frazer IH. Measuring serum antibody to human papillomavirus following infection or vaccination. Gynecol Oncol. 2010;118 Suppl 1:S8–11.PubMedCrossRef Frazer IH. Measuring serum antibody to human papillomavirus following infection or vaccination. Gynecol Oncol. 2010;118 Suppl 1:S8–11.PubMedCrossRef
5.
go back to reference Gersch ED, Gissmann L, Garcea RL. New approaches to prophylactic human papillomavirus vaccines for cervical cancer prevention. Antivir Ther. 2012;17:425–34.PubMedCrossRef Gersch ED, Gissmann L, Garcea RL. New approaches to prophylactic human papillomavirus vaccines for cervical cancer prevention. Antivir Ther. 2012;17:425–34.PubMedCrossRef
6.
go back to reference Schiller JT, Castellsagué X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine. 2012;30 Suppl 5:F123–38.PubMedCrossRef Schiller JT, Castellsagué X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine. 2012;30 Suppl 5:F123–38.PubMedCrossRef
7.
go back to reference Fehrmann F, Klumpp DJ, Laimins LA. Human papillomavirus type 31 E5 protein supports cell cycle progression and activates late viral functions upon epithelial differentiation. J Virol. 2003;77:2819–31.PubMedCentralPubMedCrossRef Fehrmann F, Klumpp DJ, Laimins LA. Human papillomavirus type 31 E5 protein supports cell cycle progression and activates late viral functions upon epithelial differentiation. J Virol. 2003;77:2819–31.PubMedCentralPubMedCrossRef
8.
go back to reference Wilson R, Fehrmann F, Laimins LA. Role of the E1–E4 protein in the differentiation-dependent life cycle of human papillomavirus type 31. J Virol. 2005;79:6732–40.PubMedCentralPubMedCrossRef Wilson R, Fehrmann F, Laimins LA. Role of the E1–E4 protein in the differentiation-dependent life cycle of human papillomavirus type 31. J Virol. 2005;79:6732–40.PubMedCentralPubMedCrossRef
10.
go back to reference Zhao KN, Gu W, Fang NX, Saunders NA, Frazer IH. Gene codon composition determines differentiation-dependent expression of a viral capsid gene in keratinocytes in vitro and in vivo. Mol Cell Biol. 2005;25:8643–55.PubMedCentralPubMedCrossRef Zhao KN, Gu W, Fang NX, Saunders NA, Frazer IH. Gene codon composition determines differentiation-dependent expression of a viral capsid gene in keratinocytes in vitro and in vivo. Mol Cell Biol. 2005;25:8643–55.PubMedCentralPubMedCrossRef
12.
go back to reference Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond). 2006;110:525–41.PubMedCrossRef Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond). 2006;110:525–41.PubMedCrossRef
14.
go back to reference Luft F, Klaes R, Nees M, Dürst M, Heilmann V, Melsheimer P, et al. Detection of integrated papillomavirus sequences by ligation-mediated PCR (DIPS-PCR) and molecular characterization in cervical cancer cells. Int J Cancer. 2001;92:9–17.PubMedCrossRef Luft F, Klaes R, Nees M, Dürst M, Heilmann V, Melsheimer P, et al. Detection of integrated papillomavirus sequences by ligation-mediated PCR (DIPS-PCR) and molecular characterization in cervical cancer cells. Int J Cancer. 2001;92:9–17.PubMedCrossRef
15.
go back to reference Yoshida T, Sano T, Kanuma T, Owada N, Sakurai S, Fukuda T, et al. Immunochemical analysis of HPV L1 capsid protein and p16 protein in liquid-based cytology samples from uterine cervical lesions. Cancer. 2008;114:83–8.PubMedCrossRef Yoshida T, Sano T, Kanuma T, Owada N, Sakurai S, Fukuda T, et al. Immunochemical analysis of HPV L1 capsid protein and p16 protein in liquid-based cytology samples from uterine cervical lesions. Cancer. 2008;114:83–8.PubMedCrossRef
16.
go back to reference Lee SJ, Lee AW, Kang CS, Park JS, Park DC, Ki EY, et al. Clinicopathological implications of Human Papilloma Virus (HPV) L1 Capsid Protein Immunoreactivity in HPV16-positive cervical cytology. Int J Med Sci. 2014;11:80–6.PubMedCentralPubMedCrossRef Lee SJ, Lee AW, Kang CS, Park JS, Park DC, Ki EY, et al. Clinicopathological implications of Human Papilloma Virus (HPV) L1 Capsid Protein Immunoreactivity in HPV16-positive cervical cytology. Int J Med Sci. 2014;11:80–6.PubMedCentralPubMedCrossRef
17.
go back to reference Macville M, Schröck E, Padilla-Nash H, Keck C, Ghadimi BM, Zimonjic D, et al. Comprehensive and definitive molecular cytogenetic characterization of HeLa cells by Spectral Karyotyping. Cancer Res. 1999;59:141–50.PubMed Macville M, Schröck E, Padilla-Nash H, Keck C, Ghadimi BM, Zimonjic D, et al. Comprehensive and definitive molecular cytogenetic characterization of HeLa cells by Spectral Karyotyping. Cancer Res. 1999;59:141–50.PubMed
18.
go back to reference Boshart M, Gissmann L, Ikenberg H, Kleinheinz A, Scheurlen W, zur Hausen H. A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer. EMBO J. 1984;3:1151–7.PubMedCentralPubMed Boshart M, Gissmann L, Ikenberg H, Kleinheinz A, Scheurlen W, zur Hausen H. A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer. EMBO J. 1984;3:1151–7.PubMedCentralPubMed
19.
go back to reference Schwarz E, Freese UK, Gissmann L, Mayer W, Roggenbuck B, Stremlau A, et al. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature. 1985;314(6006):111–4.PubMedCrossRef Schwarz E, Freese UK, Gissmann L, Mayer W, Roggenbuck B, Stremlau A, et al. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature. 1985;314(6006):111–4.PubMedCrossRef
20.
go back to reference Meissner JD. Nucleotide sequences and further characterization of human papillomavirus DNA present in the CaSki, SiHa and HeLa cervical carcinoma cell lines. J Gen Virol. 1999;80:1725–33.PubMed Meissner JD. Nucleotide sequences and further characterization of human papillomavirus DNA present in the CaSki, SiHa and HeLa cervical carcinoma cell lines. J Gen Virol. 1999;80:1725–33.PubMed
21.
go back to reference Boulet G, Horvath C, Vanden Broeck D, Sahebali S, Bogers J. Human papillomavirus: E6 and E7 oncogenes. Int J Biochem Cell Biol. 2007;39:2006–11.PubMedCrossRef Boulet G, Horvath C, Vanden Broeck D, Sahebali S, Bogers J. Human papillomavirus: E6 and E7 oncogenes. Int J Biochem Cell Biol. 2007;39:2006–11.PubMedCrossRef
22.
go back to reference Wu TC, Hsieh ST, Purow BW, Kurman RJ. Demonstration of human papillomavirus (HPV) genomic amplification and viral-like particles from CaSki cell line in SCID mice. J Virol Meth. 1997;65:287–98.CrossRef Wu TC, Hsieh ST, Purow BW, Kurman RJ. Demonstration of human papillomavirus (HPV) genomic amplification and viral-like particles from CaSki cell line in SCID mice. J Virol Meth. 1997;65:287–98.CrossRef
23.
go back to reference Wentzensen N, Ridder R, Klaes R, Vinokurova S, Schaefer U. Doeberitz Mv. Characterization of viral-cellular fusion transcripts in a large series of HPV16 and 18 positive anogenital lesions. Oncogene. 2002;21:419–26.PubMedCrossRef Wentzensen N, Ridder R, Klaes R, Vinokurova S, Schaefer U. Doeberitz Mv. Characterization of viral-cellular fusion transcripts in a large series of HPV16 and 18 positive anogenital lesions. Oncogene. 2002;21:419–26.PubMedCrossRef
24.
go back to reference Shi YM, Xiao CY, Ye H, Wang YQ, Wu JF. The detection of HPV16 L1 from cervical tissue specimen. Basic Clin Med. 2010;30:807–10. Shi YM, Xiao CY, Ye H, Wang YQ, Wu JF. The detection of HPV16 L1 from cervical tissue specimen. Basic Clin Med. 2010;30:807–10.
25.
go back to reference Yu T, Ferber MJ, Cheung TH, Chung TK, Wong YF, Smith DI. The role of viral integration in the development of cervical cancer. Cancer Genet Cytogenet. 2005;158:27–34.PubMedCrossRef Yu T, Ferber MJ, Cheung TH, Chung TK, Wong YF, Smith DI. The role of viral integration in the development of cervical cancer. Cancer Genet Cytogenet. 2005;158:27–34.PubMedCrossRef
26.
go back to reference Zhao X, Fay J, Lambkin H, Schwartz S. Identification of a 17-nucleotide splicing enhancer in HPV-16 L1 that counteracts the effect of multiple hnRNP A1-binding splicing silencers. Virology. 2007;369:351–63.PubMedCrossRef Zhao X, Fay J, Lambkin H, Schwartz S. Identification of a 17-nucleotide splicing enhancer in HPV-16 L1 that counteracts the effect of multiple hnRNP A1-binding splicing silencers. Virology. 2007;369:351–63.PubMedCrossRef
27.
go back to reference Wang X, Meyers C, Wang HK, Chow LT, Zheng ZM. Construction of a full transcription map of human papillomavirus type 18 during productive viral infection. J Virol. 2011;85:8080–92.PubMedCentralPubMedCrossRef Wang X, Meyers C, Wang HK, Chow LT, Zheng ZM. Construction of a full transcription map of human papillomavirus type 18 during productive viral infection. J Virol. 2011;85:8080–92.PubMedCentralPubMedCrossRef
29.
go back to reference Chen XS, Garcea RL, Goldberg I, Casini G, Harrison SC. Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol Cell. 2000;5:557–67.PubMedCrossRef Chen XS, Garcea RL, Goldberg I, Casini G, Harrison SC. Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol Cell. 2000;5:557–67.PubMedCrossRef
30.
go back to reference Lee H, Lee KJ, Jung CK, Hong JH, Lee YS, Choi YJ, et al. Expression of HPV L1 capsid protein in cervical specimens with HPV infection. Diagn Cytopathol. 2008;36:864–7.PubMedCrossRef Lee H, Lee KJ, Jung CK, Hong JH, Lee YS, Choi YJ, et al. Expression of HPV L1 capsid protein in cervical specimens with HPV infection. Diagn Cytopathol. 2008;36:864–7.PubMedCrossRef
31.
go back to reference Xiao W, Bian M, Ma L, Liu J, Chen Y, Yang B, et al. Immunochemical analysis of human papillomavirus L1 capsid protein in liquid-based cytology samples from cervical lesions. Acta Cytol. 2010;54:661–7.PubMed Xiao W, Bian M, Ma L, Liu J, Chen Y, Yang B, et al. Immunochemical analysis of human papillomavirus L1 capsid protein in liquid-based cytology samples from cervical lesions. Acta Cytol. 2010;54:661–7.PubMed
32.
go back to reference Jiang BL, Xiao CY, Yuan TN, Ye H, Wang YQ, Li JH, et al. Humoral immunity characteristics of a conserved sequence on the C-terminal region of the human papillomavirus major protein Ll. Immunological J. 2009;25:239–42. Jiang BL, Xiao CY, Yuan TN, Ye H, Wang YQ, Li JH, et al. Humoral immunity characteristics of a conserved sequence on the C-terminal region of the human papillomavirus major protein Ll. Immunological J. 2009;25:239–42.
33.
go back to reference Zhang T, Xu Y, Qiao L, Wang Y, Wu X, Xu X, et al. Trivalent Human Papillomavirus (HPV) VLP vaccine covering HPV type 58 can elicit high level of humoral immunity but also induce interference among component types. Vaccine. 2010;28:3479–87.PubMedCrossRef Zhang T, Xu Y, Qiao L, Wang Y, Wu X, Xu X, et al. Trivalent Human Papillomavirus (HPV) VLP vaccine covering HPV type 58 can elicit high level of humoral immunity but also induce interference among component types. Vaccine. 2010;28:3479–87.PubMedCrossRef
Metadata
Title
Observations on the expression of human papillomavirus major capsid protein in HeLa cells
Authors
Chang-Yi Xiao
Bing-Bing Fu
Zhi-Ying Li
Gohar Mushtaq
Mohammad Amjad Kamal
Jia-Hua Li
Gui-Cheng Tang
Shuo-Shuang Xiao
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2015
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-015-0206-0

Other articles of this Issue 1/2015

Cancer Cell International 1/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine